[123I/18F] N-(2-aminoethyl)-5-halogeno-2-pyridinecarbox-amides, site specific tracers for MAO-B mapping with SPECT and PET.
After the successful 123I-labelling of Ro 43-0463 the new radiopharmaceutical was tested in animals and humans. Both investigations proved the binding of the labelled compound to cerebral MAO-B. SPECT investigations resulted in an imaging of the MAO-B distribution in the human brain. This prompted us to develop the labelling of this type of MAO-B inhibitor with 18F enabling us to transfer our results to PET.
Beer
H F
HF
Radiopharmacy Division, Paul Scherrer Institute, Villigen, Switzerland.
Frey
L D
LD
Häberli
M
M
Schubiger
P A
PA
D000818:Animals; D001345:Autoradiography; D001921:Brain / Q000033:anatomy & histology / Q000201:enzymology*; D001931:Brain Mapping / Q000379:methods*; D005462:Fluorine Radioisotopes; D006801:Humans; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000138:chemical synthesis*; D011725:Pyridines / Q000138:chemical synthesis* / Q000494:pharmacology; D011849:Radioactive Tracers; D051381:Rats; D014055:Tomography, Emission-Computed; D015899:Tomography, Emission-Computed, Single-Photon
D005462:Fluorine Radioisotopes; D007457:Iodine Radioisotopes; D008996:Monoamine Oxidase Inhibitors; D011725:Pyridines; D011849:Radioactive Tracers; D008995:Monoamine Oxidase